| Entrectinib studied in …STUDIED_INderived33 of 33show fewer |
|---|
| → studied in | NCT03994796Phase 2 · active not recruiting Genetic Testing in Guiding Treatment for Patients With Brain Metastases · 33 trials list this drug (20 active) | — | — | Malignant Solid Neoplasm,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02650401Phase 1/Phase 2 · active not recruiting Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options · 33 trials list this drug (20 active) | — | — | Solid Neoplasm,Central Nervous System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04302025Phase 2 · recruiting A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 33 trials list this drug (20 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178552Phase 2/Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05862285Phase 3 · recruiting A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study · 33 trials list this drug (20 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568267Phase 2 · active not recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) · 33 trials list this drug (20 active) | — | — | Head and Neck Neoplasm,Adult Solid Neoplasm,Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04603807Phase 3 · active not recruiting A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05170204Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05722886Phase 2/Phase 3 · recruiting DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol · 33 trials list this drug (20 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05525858recruiting KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II · 33 trials list this drug (20 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06528691Phase 2 · recruiting Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors · 33 trials list this drug (20 active) | — | — | Central Nervous System Neoplasm,High-Grade Glioma, NOS | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05396859Phase 1 · active not recruiting Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · 33 trials list this drug (20 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05770544Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. · 33 trials list this drug (20 active) | — | — | Neoplasm by Site,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 33 trials list this drug (20 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07199959recruiting Study on the Mechanism of Acquired Resistance of Entrectinib · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 33 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06482086Phase 2 · recruiting Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer · 33 trials list this drug (20 active) | — | — | Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551495Phase 2 · unknown Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) · 33 trials list this drug (20 active) | — | — | Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694129not yet recruiting Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC · 33 trials list this drug (20 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 33 trials list this drug (20 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 33 trials list this drug (20 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 33 trials list this drug (20 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 33 trials list this drug (20 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 33 trials list this drug (20 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589832Phase 1/Phase 2 · terminated Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma · 33 trials list this drug (20 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 33 trials list this drug (20 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02097810Phase 1 · completed Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. · 33 trials list this drug (20 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03961100Phase 1 · completed A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. · 33 trials list this drug (20 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02587650Phase 2 · terminated Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma · 33 trials list this drug (20 active) | — | — | Cutaneous Melanoma,Invasive Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03066661no longer available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions · 33 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03330990Phase 1 · completed Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients · 33 trials list this drug (20 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |